Valproate (Depakote) During Pregnancy: Risks Explained

What does the evidence say about valproate during pregnancy?

1. MotherToBaby reports about 10% major defects after first-trimester valproic-acid exposure, with neural-tube-defect risk around 1% to 2%, and notes possible neurodevelopmental effects. 1
2. A review of antiepileptic-drug teratogenicity summarizes registry and meta-analysis findings showing dose-related valproate risk for major malformations and behavioral or cognitive effects. 2
3. A review of pregnancy registries reports consistently higher major-congenital-malformation risk with valproate monotherapy than with several other antiseizure medicines and describes dose dependence. 3
4. A clinical review describes valproate's high malformation and neurodevelopmental risk and emphasizes shared decision-making because stopping may also endanger seizure or mood control. 4
5. A pregnancy-and-epilepsy review reports major-malformation risk around 6% to 9% for valproate and describes a dose-associated pattern compared with lamotrigine or carbamazepine. 5

Is valproate safe in each trimester?

• First trimester. First-trimester valproate exposure is associated with major congenital malformations, including neural-tube defects, and risk rises with dose in registry studies. Contact the prescriber promptly after exposure rather than stopping abruptly.
• Second trimester. Later exposure still matters because neurodevelopmental and growth outcomes have been studied beyond structural development. Keep seizure or mood control coordinated while specialists review the lowest-risk effective plan.
• Third trimester. Tell the delivery and newborn teams about valproate exposure. Newborns may need observation for temporary jitteriness, irritability, low blood sugar, or other adaptation concerns described in medication references.